# Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

> **NCT03099564** · EARLY_PHASE1 · UNKNOWN · sponsor: **Ashwin Somasundaram** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** Y90 radioembolization

## Key facts

- **NCT ID:** NCT03099564
- **Lead sponsor:** Ashwin Somasundaram
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-28
- **Primary completion:** 2021-05-19
- **Final completion:** 2023-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099564, "Pembrolizumab Plus Y90 Radioembolization in HCC Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03099564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*